|
業務類別
|
Biotechnology |
|
業務概覽
|
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01:proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment;and LTI-05 and others. |
| 公司地址
| 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758 |
| 電話號碼
| +1 737 802-1989 |
| 傳真號碼
| +1 617 995-2410 |
| 公司網頁
| https://www.reintx.com |
| 員工數量
| 11 |
| Dr. James Brian Windsor, PhD |
Chief Executive Officer, President and Director |
美元 506.25K |
12/05/2025 |
| Mr. Timothy M. Cunningham |
Interim Chief Financial Officer and Principal Accounting Officer |
-- |
12/05/2025 |
|
|
| Dr. James Brian Windsor, PhD |
Chief Executive Officer, President and Director |
12/05/2025 |
| Mr. Joseph H. Von Rickenbach |
Chairman of the Board |
12/05/2025 |
| Dr. Reinhard J. Ambros, PhD |
Independent Director |
12/05/2025 |
| Mr. William Carl Fairey, Jr |
Independent Director |
12/05/2025 |
| Mr. Alan A. Musso |
Independent Director |
12/05/2025 |
|
|
|
|
